NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.20 +0.25 (+0.32%) GOLD FUTURES
2,312.50 +2.90 (+0.13%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,299.43 +1,105.97 (+2.39%)
China Medical System Holdings Limited (0867.HK)
| Previous close | 7.010 |
| Open | 7.010 |
| Bid | 7.380 x 0 |
| Ask | 7.390 x 0 |
| Day's range | 6.890 - 7.380 |
| 52-week range | 6.850 - 15.860 |
| Volume | |
| Avg. volume | 7,839,510 |
| Market cap | 18.004B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 6.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.43 (6.11%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that
- GlobeNewswire
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a
- GlobeNewswire
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and normalized profit for the year that excluding provisions of impairment losses
